Syncona appoints John Roche as an independent Non-Executive Director

Syncona

Syncona Ltd (LON:SYNC), a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science, has announced the appointment of John Roche as an independent Non-Executive Director, with effect from 1 October 2024.

John brings many years of broad financial experience to the role, having spent more than 15 years as a Partner at PricewaterhouseCoopers (PwC) in Guernsey. During this time he served as managing partner of the Guernsey office for seven years and was leader of the Capital Markets Practice for twelve years. While at PwC, John specialised in providing audit and capital markets advisory services to listed investment companies and alternative asset management clients, developing extensive valuation experience.

John is a Fellow of the Institute of Chartered Accountants in Ireland, who retired from practice in 2022. He is a Non-Executive Director and Chair of the Audit Committee of Riverstone Energy Limited, a London-listed investment company, and a Guernsey resident.

On appointment, John will join the Company’s Audit Committee.

Melanie Gee, Chair of Syncona Ltd, said: “We are delighted to welcome John to Syncona. He brings significant financial experience to the Board, and we look forward to benefitting from his breadth of knowledge and expertise as we support the Syncona team to deliver our long-term strategy and growth ambitions.”

John Roche said: “I am delighted to be joining Syncona. I look forward to working closely with my Board colleagues and the broader Syncona team as they continue to invest to extend and enhance human life.”

Share on:

Latest Company News

Syncona outlines £250m shareholder return plan and refined investment strategy

Syncona has announced a new set of proposals focused on returning £250 million to shareholders through future portfolio realisations and refining its investment strategy to maximise long-term value.

Syncona proposes investment policy change

Syncona Limited is revamping its investment strategy to enhance shareholder value amid challenging biotech market conditions. Explore their proposed policy changes and cash return options.

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP).

Syncona launches Slingshot to advance early-stage biotech innovations

Syncona Ltd launches Slingshot Therapeutics, investing £12.5 million to advance academic innovations into biotech with a focus on inflammatory diseases.

Syncona portfolio company Beacon Therapeutics raises $170 million in a Series B financing

Syncona Ltd (LON:SYNC) commits $42.5 million to Beacon Therapeutics' $170 million Series B financing to advance treatments for blinding retinal diseases.

    Search

    Search